Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings

Wilailak, Sarikapan; Chan, Karen Kar Loen; Chen, Chi-An; Nam, Joo Hyun; Ochiai, Kazunori; Aw, Tar Choon; Sabaratnam, Subathra; Hebbar, Sudarshan; Sickan, Jaganathan; Schodin, Beth A.; Charakorn, Chuenkamon; Sumpaico, Walfrido W.

doi:10.3802/jgo.2015.26.1.46

Cited by 42 publications

(36 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although Wilailak et al, (2015) (AuROC 89.3%) and Yanaranop et al, (2016) (AuROC 92.8%) reported the use of HE-4 as a predictive parameter, we did not insert HE-4 within our model because it was not widely used in our clinical setting due to limited expenses, and usually required longer waiting time for the result. With categorization of continuous variables and exclusion of variables from previously reported models, five parameters were left within our scoring scheme.…”

Section: Discussionmentioning

confidence: 99%

“…Many preoperative prediction tools for ovarian cancer were consistently developed in many institutions e.g. The Risk of Malignancy Index I-IV (Jacobs et al, 1990;Tingulstad et al, 1996;Tingulstad et al, 1999;Yamamoto et al, 2009), The Risk of Malignancy Algorithms, an ultrasound prediction model developed by the International Ovarian Tumor Analysis (IOTA) study (Moore et al, 2009), Rajavithi-Ovarian cancer predictive score (Yanaranop et al, 2016) and algorithm with HE4, menopausal status and ultrasound findings (Wilailak et al, 2015). However, none of them can effectively distinguish between early and advanced stage ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development and Validation of a Predictive Score for Preoperative Diagnosis of Early Stage Epithelial Ovarian Cancer

Chirdchim

Wanichsetakul

Phinyo

et al. 2019

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Objective: To develop and validate a simplified multi-parameter risk-based scoring system for preoperative diagnosis of early stage epithelial ovarian cancer. Methods: All women presented with adnexal mass and were scheduled for operation at Phrapokklao hospital during September 2013 -December 2017 were included and categorized according to their histopathologic reports into early stage ovarian cancer groups and benign ovarian tumor groups. Multivariable logistic regression was used to explore for potential predictors. The selected logistic coefficients were transformed into risk-based scoring system. Internal validation was done with bootstrapping procedure. Results: A total of 270 participants were included in analysis and predictive model development, 54 in early stage ovarian cancer group and 216 in benign ovarian tumor group. Menopausal status, two abnormal ultrasound findings (presence of solid component or ascites), tumor size and serum CA-125 level were used for derivation of the scoring system. The score-based model showed area under ROC of 0.88 (95%CI 0.82-0.93). The developed scoring system ranged from 0 to 51 was classified into 3 subcategories for clinical practicability. The positive predictive values for the presence of early stage ovarian cancer were 2.07 (95%CI 0.43-6.05) for low risk patient, for moderate risk patient,) for high risk patient. Conclusion: This simplified risk-based scoring system for preoperative diagnosis of early stage ovarian cancer could aid general physicians or general gynecologists in evaluation of patients presenting with ovarian tumors and help gynecologic oncologists in management planning and prioritization of patients for operation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Development and Validation of a Predictive Score for Preoperative Diagnosis of Early Stage Epithelial Ovarian Cancer

Chirdchim

Wanichsetakul

Phinyo

et al. 2019

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…It has been more helpful for diagnosis than for monitoring therapeutic response. HE-4 has most frequently been used in conjunction with CA125 and other factors to distinguish ovarian cancer from a benign abdominal process 40,46,47. The mucin-like TAG-72 is generally expressed on adenocarcinomas and less frequently in other types of malignancies 48–50.…”

Section: Discussionmentioning

confidence: 99%

Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab

Meredith¹,

Torgue

Rozgaja

et al. 2018

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Purpose:One-year monitoring of patients receiving intraperitoneal (IP) 212Pb-TCMC-trastuzumab to provide long-term safety and outcome data. A secondary objective was to study 7 tumor markers for correlation with outcome.Methods:Eighteen patients with relapsed intra-abdominal human epidermal growth factor receptor-2 expressing peritoneal metastases were treated with a single IP infusion of 212Pb-TCMC-trastuzumab, delivered <4 h after 4 mg/kg IV trastuzumab. Seven tumor markers were studied for correlation with outcome.Results:Six dose levels (7.4, 9.6, 12.6, 16.3, 21.1, 27.4 MBq/m2) were well tolerated with early possibly agent-related adverse events being mild, transient, and not dose dependent. These included asymptomatic, abnormal laboratory values. No late renal, liver, cardiac, or other toxicity was noted up to 1 year. There were no clinical signs or symptoms of an immune response to 212Pb-TCMC-trastuzumab, and assays to detect an immune response to this conjugate were negative for all tested. Tumor marker studies in ovarian cancer patients showed a trend of decreasing Cancer antigen 72-4 (CA 72-4) aka tumor-associated glycoprotein 72 (TAG-72) and tumor growth with increasing administered radioactivity. Other tumor markers, including carbohydrate antigen (CA125), human epididymis protein 4 (HE-4), serum amyloid A (SAA), mesothelin, interleukin-6 (IL-6), and carcinoembryonic antigen (CEA) did not correlate with imaging outcome.Conclusions:IP 212Pb-TCMC-trastuzumab up to 27 MBq/m2 seems safe for patients with peritoneal carcinomatosis who have failed standard therapies. Serum TAG-72 levels better correlated to imaging changes in ovarian cancer patients than the more common tumor marker, CA125.

show abstract

“…In order to increase the sensitivity and specificity for the detection of EOC, a number of novel markers have been investigated, including matrix metalloproteinase-1, osteopontin, and human epididimis 4 [4][5][6]. Of these, high mobility group box 1 (HMGB1) was characterized as a non-histone, nuclear DNA-binding protein [7].…”

Section: Introductionmentioning

confidence: 99%

“…However, its utility as a screening marker is limited due to its low sensitivity and specificity [2]. Moreover, the serum level of CA125 can be elevated in other cancers such as uterine cancer, gastrointestinal cancer, as well as in benign disease [3].In order to increase the sensitivity and specificity for the detection of EOC, a number of novel markers have been investigated, including matrix metalloproteinase-1, osteopontin, and human epididimis 4 [4][5][6]. Of these, high mobility group box 1 (HMGB1) was characterized as a non-histone, nuclear DNA-binding protein [7].…”

mentioning

confidence: 99%

The expression of HMGB1 and the receptor for advanced glycation end products (RAGE) in epithelial ovarian cancer

Paek¹,

Kim²

2017

Integr Cancer Sci Therap.

View full text Add to dashboard Cite

examined whether the expression of mRNA HMGB1 and RAGE were associated with the development of EOC and evaluated the correlation of the serum HMGB1 level and EOC. Materials and methods PatientsA total of 78 women who underwent surgery for a pelvic mass from May 2009 to February 2011 were included in this study. Their blood samples were collected before they received surgery and their ovarian tissues were selectively sampled during the operation. All surgical tissues were examined by a gynecologic pathologist and final surgical pathology reports were obtained and recorded. The chemotherapy regimen was 6 cycles of paclitaxel 175 mg/m 2 and carboplatin at the area under curve of 5. The baseline patient characteristics included patient age, body mass index, performance status, tumor stage, and tumor grade. Performance status was defined according to Gynecologic Oncology Group criteria as: 0 = normal activity; 1 = symptomatic, fully ambulatory; 2 = symptomatic, in bed less than 50% of the time. Written informed consent was obtained from all patients prior to collection of blood and surgery. This research was approved by the Institutional Review Board of Yonsei University Health System. AbstractThe aim of this study was to confirm the expression of high mobility group box 1 (HMGB1) and its receptor for advanced glycation end products (RAGE) in patients with epithelial ovarian cancer (EOC). A total of 78 patients with EOC comprised our cohort. They received debulking surgery followed by taxane and platinum chemotherapy. The mRNA levels of HMGB1 and RAGE in ovarian tissues obtained from surgery were detected using reverse transcription-PCR. In addition, the serum levels of HMGB1 were evaluated between cancer and non-cancer group. The mRNA levels of HMGB1 were higher in EOC compared to the non-cancer cohort (0.94 vs. 0.90) and there was no statistically significant difference. Similarly, the mRNA levels of RAGE did not differ between the EOC and non-cancer cohort. The serum HMGB1 levels were not greater in the cancer cohort than the non-cancer cohort (0.40 vs. 0.45 ng/mL, P=0.106). Contrary to expectations as a promising biomarker for EOC, the expression of both HMGB1 and RAGE did not show significant differences in EOC group. Further studies are needed to assess potential roles in EOC. IntroductionEpithelial ovarian cancer (EOC) is the fourth most common cause of cancer-related death in women worldwide, accounting for approximately 3% of all new cancer patients in 2009 [1]. Unfortunately, most of the patients are diagnosed with an advanced stage of EOC. Currently, there is no proven effective method for early detection in EOC and only the serum CA125 level has been used to predict the presence of cancer. However, its utility as a screening marker is limited due to its low sensitivity and specificity [2]. Moreover, the serum level of CA125 can be elevated in other cancers such as uterine cancer, gastrointestinal cancer, as well as in benign disease [3].In order to increase the sensitivity and specificity for the detecti...

show abstract

Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings

Cited by 42 publications

References 25 publications

Development and Validation of a Predictive Score for Preoperative Diagnosis of Early Stage Epithelial Ovarian Cancer

Development and Validation of a Predictive Score for Preoperative Diagnosis of Early Stage Epithelial Ovarian Cancer

Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab

The expression of HMGB1 and the receptor for advanced glycation end products (RAGE) in epithelial ovarian cancer

Contact Info

Product

Resources

About